logo-loader
viewOpen Orphan PLC

Open Orphan first half: 'period of integration, restructuring and setting the scene' for future growth

Proactive Analyst Emma Ulker talks through how Open Orphan (LON:ORPH) performed in the first half of the year. 

In the six-month period to June 2020, the company focused on integration and restructuring following its acquisition of lab services and challenge studies specialist hVIVO in January.

The company reported £7.1mln of H1 2020 revenues on a reported basis, (no comparable revenues in H1 2019).

Click here to read Emma Ulker's latest research update

Quick facts: Open Orphan PLC

Price: 25 GBX

AIM:ORPH
Market: AIM
Market Cap: £166.99 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Open Orphan PLC named herein, including the promotion by the Company of Open Orphan PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Open Orphan present at the Proactive One2one virtual investment forum

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual October Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical...

1 week, 1 day ago

2 min read